"10.1371_journal.pone.0029181","plos one","2012-03-12T00:00:00Z","Myrna Candelaria; Erick de la Cruz-Hernandez; Lucia Taja-Chayeb; Enrique Perez-Cardenas; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Alma Chavez-Blanco; Ernesto Soto-Reyes; Guadalupe Dominguez; Jaenai E Trujillo; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez","Division of Clinical Research, Instituto Nacional de Cancerologia, Mexico City, Mexico; Division of Basic Research, Instituto Nacional de Cancerologia, Mexico City, Mexico; Unit of Biomedical Research in Cancer. Instituto Nacional de Cancerologia/Instituto de Investigaciones Biomedicas UNAM, Mexico City, Mexico","Conceived and designed the experiments: ADG. Performed the experiments: MC ECH LTC EPC CTB AGF ACB ES GD JT JD-C. Analyzed the data: MC LTC. Contributed reagents/materials/analysis tools: ECH LTC EPC CTB AGF ACB. Wrote the paper: MC ADG.","ADG has received paid consultancy from Psicofarma S.A. de C.V. for matters other than those related to this research. The author's Institution (National Autonomous University of Mexico)has patent applications concerning hydralazine. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2012","03","Myrna Candelaria","MC",12,TRUE,1,11,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
